Biotech & pharmaceutical Strategy Consulting
Discover optimal partnering opportunities
Biotech & pharmaceutical Strategy Consulting
Discover optimal partnering opportunities
Discover optimal partnering opportunities
Discover optimal partnering opportunities
Twenty-five+ years of Biotech and Pharma experience working in management and as a business consultant primarily for start-ups, but also for multinational corporations. 30+ publications in trade journals and reports.
Define projects with specific deliverables. and Complete all engagements with high quality, on time and within budget. We obtain qualitative data from primary interviews with industry experts and executives.
Serving a broad range of therapeutic indications such as Oncology, Immunology, Cardiovascular, Neurological, Metabolic, and various (orphan status) rare disorders.
Advanced technologies such as AI drug discovery, monoclonal and next generation antibodies, Bio- and chemo-informatics, cell and gene therapies e.g. CAR T therapeutics, small molecules, biologic tools and platform technologies e.g. combinatorial chemistry, automated high-throughput gene sequencing, and mass spec analysis.
Identify potential partners, suitors, and champions to generate synergy through complementary capabilities that create real value.
Leverage or seek platform technologies and/or specific domain expertise to generate and develop new molecular entities (NMEs) that closely match portfolio and mission objectives. Bring or seek partners with clinical trial experience, pilot and scale-up manufacturing knowledge, the ability to navigate through the regulatory approval process, and the resources to market and launch a new product.
Create functional, reliable and durable relationships between senior management of each organization that possess an excellent technical and cultural fit. Identify and articulate key objectives and aspirations where communication is paramount.
Conduct an open and thorough discussion on how the asset valuation was developed and negotiate the specifics of the term sheet for any research collaborations / in- or out-licensing deal. Negotiations may include, but are not limited to, the ownership of assets, therapeutic indications, geographic territories, upfront, milestones, royal rates (tiered), additional indications, and terms if the collaboration is prematurely terminated.
Understand the current status of the main 5 forces acting on the Biotech and Pharma industry. How will scientific and technical advancements impact all phases of discovery, development and marketing of new, reformulated, generic, biosimilar and repurposed drugs. What are your competitors strategies? What choices does your organization make to create its own competitive strategy?
Formulate the optimal use of internal resources, intellectual properties, technologies and methods to maximize growth. Evaluate the present pipeline/portfolio management in order to meet technical and financial objectives ever mindful of the budget, capital burn rate and runway.
Be prepared and well-organized for scientific/technical, IP (legal) and financial due diligence requests from prospective suitors and collaborators and financiers.
Comprehensive evaluation of comparative deals. Generation of probability weighted, (risk-adjusted) NPV valuations for all potential therapeutic indications through each stage of development.
Evaluate technical advantages and caveats, capacity, intellectual property and competitors in the marketplace with market sizing, market share, pricing, forecasting. Critical analysis of emerging or disruptive technologies.
How does your company present the benefits of your product for each market segment? How does your product stand up to the competition with each target audience? Do you package your savoir−faire as products services or both?
San Diego, CA USA and Paris, France
Copyright © 2024 Etoile Pharma - All Rights Reserved.